Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

        
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months

- Initiated utilization of share repurchase program

- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, 
reinforcing financial stability

Read more at globenewswire.com